Differential Gene Expression Profiles May Differentiate Responder and Nonresponder Patients with Rheumatoid Arthritis for Methotrexate (MTX) Monotherapy and MTX plus Tumor Necrosis Factor Inhibitor Combined Therapy


Autoria(s): Oliveira, Renê Donizeti Ribeiro de; Fontana, Vanessa; Junta, Cristina Moraes; Marques, Marcia Maria Chiquitelli; Macedo, Claudia; Rassi, Diane Meyre; Passos, Geraldo Aleixo; Donadi, Eduardo Antonio; Louzada-Junior, Paulo
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

06/11/2013

06/11/2013

2012

Resumo

Objective. We aimed to evaluate whether the differential gene expression profiles of patients with rheumatoid arthritis (RA) could distinguish responders from nonresponders to methotrexate (MTX) and, in the case of MTX nonresponders, responsiveness to MTX plus anti-tumor necrosis factor-alpha (anti-TNF) combined therapy. Methods. We evaluated 25 patients with RA taking MTX 15-20 mg/week as a monotherapy (8 responders and 17 nonresponders). All MTX nonresponders received intliximab and were reassessed after 20 weeks to evaluate their anti-TNF responsiveness using the European League Against Rheumatism response criteria. A differential gene expression analysis from peripheral blood mononuclear cells was performed in terms of hierarchical gene clustering, and an evaluation of differentially expressed genes was performed using the significance analysis of microarrays program. Results. Hierarchical gene expression clustering discriminated MTX responders from nonresponders, and MTX plus anti-TNF responders from nonresponders. The evaluation of only highly modulated genes (fold change > 1.3 or < 0.7) yielded 5 induced (4 antiapoptotic and CCL4) and 4 repressed (4 proapoptotic) genes in MTX nonresponders compared to responders. In MTX plus anti-TNF nonresponders, the CCL4, CD83, and BCL2A1 genes were induced in relation to responders. Conclusion. Study of the gene expression profiles of RA peripheral blood cells permitted differentiation of responders from nonresponders to MTX and anti-TNF. Several candidate genes in MTX non-responders (CCL4, HTRA2, PRKCD, BCL2A1, CAV1, TNIP1 CASP8AP2, MXD1, and BTG2) and 3 genes in MTX plus anti-TNF nonresponders (CCL4, CD83, and BCL2A1) were identified for further study. (First Release July 1 2012; J Rheumatol 2012;39:1524-32; doi:10.3899/jrheum.120092)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo

Fundacao de Apoio ao Ensino Pesquisa e Assistencia do HC, Faculdade de Medicina de Ribeirao Preto, USP

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico

Identificador

JOURNAL OF RHEUMATOLOGY, TORONTO, v. 39, n. 8, pp. 1524-1532, AUG, 2012

0315-162X

http://www.producao.usp.br/handle/BDPI/42150

10.3899/jrheum.120092

http://dx.doi.org/10.3899/jrheum.120092

Idioma(s)

eng

Publicador

J RHEUMATOL PUBL CO

TORONTO

Relação

JOURNAL OF RHEUMATOLOGY

Direitos

closedAccess

Copyright J RHEUMATOL PUBL CO

Palavras-Chave #RHEUMATOID ARTHRITIS #MICROARRAY ANALYSIS #METHOTREXATE #MONOCLONAL ANTIBODIES #TREATMENT OUTCOME #BLOOD MONONUCLEAR-CELLS #NF-KAPPA-B #MICROARRAY ANALYSIS #BIOLOGICS REGISTER #BRITISH SOCIETY #SHARED EPITOPE #SYNOVIAL-CELLS #INFLIXIMAB #APOPTOSIS #POLYMORPHISMS #RHEUMATOLOGY
Tipo

article

original article

publishedVersion